Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
Castle Biosciences (Nasdaq: CSTL) will present new data on its DecisionDx-Melanoma and MyPath Melanoma tests at the American Society of Dermatopathology 61st Annual Meeting in Chicago, November 7-10. The presentations will showcase the clinical performance of these tests in risk-stratification for patients with confirmed or suspected melanoma.
Two posters will be presented by Dr. Etan Marks during a poster defense session on November 9. The first poster focuses on the integrated 31-gene expression profile test for melanoma recurrence risk stratification, while the second discusses statistical methods for assessing the diagnostic performance of the 23-gene expression profile test for cutaneous melanocytic neoplasms.
Castle Biosciences (Nasdaq: CSTL) presenterà nuovi dati sui suoi test DecisionDx-Melanoma e MyPath Melanoma durante il 61° Congresso Annuale della American Society of Dermatopathology a Chicago, dal 7 al 10 novembre. Le presentazioni metteranno in evidenza le performance cliniche di questi test nella stratificazione del rischio per i pazienti con melanoma confermato o sospettato.
Due poster saranno presentati dal Dr. Etan Marks durante una sessione di difesa dei poster il 9 novembre. Il primo poster si concentra sul test integrato del profilo di espressione genica a 31 geni per la stratificazione del rischio di recidiva del melanoma, mentre il secondo discute i metodi statistici per valutare la performance diagnostica del test del profilo di espressione genica a 23 geni per neoplasie melanocitiche cutanee.
Castle Biosciences (Nasdaq: CSTL) presentará nuevos datos sobre sus pruebas DecisionDx-Melanoma y MyPath Melanoma en la 61ª Reunión Anual de la American Society of Dermatopathology en Chicago, del 7 al 10 de noviembre. Las presentaciones mostrarán el rendimiento clínico de estas pruebas en la estratificación del riesgo para pacientes con melanoma confirmado o sospechado.
Dos carteles serán presentados por el Dr. Etan Marks durante una sesión de defensa de carteles el 9 de noviembre. El primer cartel se centra en la prueba integrada del perfil de expresión génica de 31 genes para la estratificación del riesgo de recurrencia del melanoma, mientras que el segundo discute los métodos estadísticos para evaluar el rendimiento diagnóstico de la prueba del perfil de expresión génica de 23 genes para neoplasias melanocíticas cutáneas.
Castle Biosciences (Nasdaq: CSTL)는 11월 7일부터 10일까지 시카고에서 열리는 제61회 미국 피부병리학회 연례 회의에서 DecisionDx-Melanoma 및 MyPath Melanoma 테스트에 대한 새로운 데이터를 발표할 예정입니다. 발표에서는 확진되거나 의심되는 흑색종 환자의 위험 분류를 위한 이러한 테스트의 임상 성능을 보여줄 것입니다.
두 개의 포스터가 11월 9일 Etan Marks 박사에 의해 포스터 방어 세션에서 발표될 것입니다. 첫 번째 포스터는 흑색종 재발 위험 분류를 위한 통합 31개 유전자 발현 프로파일 테스트에 중점을 두고 있으며, 두 번째 포스터는 피부 멜라닌세포 신생물에 대한 23개 유전자 발현 프로파일 테스트의 진단 성능을 평가하기 위한 통계적 방법에 대해 논의합니다.
Castle Biosciences (Nasdaq: CSTL) présentera de nouvelles données sur ses tests DecisionDx-Melanoma et MyPath Melanoma lors de la 61e Réunion Annuelle de l'American Society of Dermatopathology à Chicago, du 7 au 10 novembre. Les présentations mettront en avant la performance clinique de ces tests dans la stratification du risque pour les patients atteints de mélanome confirmé ou suspect.
Deux affiches seront présentées par le Dr Etan Marks lors d'une session de défense d'affiches le 9 novembre. La première affiche se concentre sur le test intégré du profil d'expression génique de 31 gènes pour la stratification du risque de récidive du mélanome, tandis que la seconde discute des méthodes statistiques pour évaluer la performance diagnostique du test du profil d'expression génique de 23 gènes pour les néoplasmes mélanocytaires cutanés.
Castle Biosciences (Nasdaq: CSTL) wird auf dem 61. Jahresmeeting der American Society of Dermatopathology in Chicago vom 7. bis 10. November neue Daten zu seinen Tests DecisionDx-Melanoma und MyPath Melanoma präsentieren. Die Präsentationen werden die klinische Leistungsfähigkeit dieser Tests bei der Risikostratifizierung von Patienten mit bestätigtem oder verdächtigem Melanom hervorgehen.
Während einer Poster-Präsentation am 9. November werden zwei Poster von Dr. Etan Marks vorgestellt. Das erste Poster konzentriert sich auf den integrierten 31-Gen-Expressionstest zur Risikostratifizierung für Melanomrezidive, während das zweite die statistischen Methoden zur Bewertung der diagnostischen Leistung des 23-Gen-Expressionstests für kutane melanocytären Neoplasien behandelt.
- None.
- None.
“At Castle, we focus strongly on continued evidence development to demonstrate where our tests might be able to add value to clinical decision-making,” said Rebecca Critchley-Thorne, Ph.D., vice president of research and development at Castle Biosciences. “Our data to be presented at ASDP support the ability of our tests to provide accurate risk-stratification in patients with confirmed or suspected melanoma, which can help clinicians make more informed treatment and management decisions in the care of their patients.”
Castle’s posters at ASDP will be presented by study author Etan Marks, D.O., board-certified dermatopathologist, laboratory director and primary investigator at Advanced Dermatology and Cosmetic Surgery in
DecisionDx-Melanoma
- Poster 231: The integrated 31-gene expression profile test stratifies recurrence risk within cutaneous melanoma subtypes
MyPath Melanoma
- Poster 232: Appropriate statistical methods to assess cross-study diagnostic 23-gene expression profile test performance for cutaneous melanocytic neoplasms
About DecisionDx®-Melanoma
DecisionDx-Melanoma is a gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient’s individual risk of sentinel lymph node positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma’s clinical value is supported by more than 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test’s results. Through Sept. 30, 2024, DecisionDx-Melanoma has been ordered approximately 183,000 times for patients diagnosed with cutaneous melanoma. Learn more at www.CastleBiosciences.com.
About MyPath® Melanoma
MyPath Melanoma is Castle’s gene expression profile test designed to provide an accurate, objective result to aid dermatopathologists and dermatologists in characterizing difficult-to-diagnose melanocytic lesions. Of the approximately two million suspicious pigmented lesions biopsied annually in the
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the ability of the DecisionDx-Melanoma and MyPath Melanoma tests to provide accurate risk-stratification in patients with confirmed or suspected melanoma and help clinicians make more informed treatment and management decisions in the care of their patients. The words “believe,” “can,” “could,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended Sept. 30, 2024 and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241108994191/en/
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: Castle Biosciences, Inc.
FAQ
What new data will Castle Biosciences present at ASDP 2023?
When and where will Castle Biosciences (CSTL) present at ASDP 2023?
What are the two posters Castle Biosciences (CSTL) will present at ASDP 2023?
